149 related articles for article (PubMed ID: 32213285)
1. Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy
.
Mosna K; Ladicka M; Drgona L; Vranovska M; Hojsikova I; Tomasova R; Danihel L; Kyselovic J; Babal P
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):343-350. PubMed ID: 32213285
[TBL] [Abstract][Full Text] [Related]
2. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
[TBL] [Abstract][Full Text] [Related]
3. Progressive Multifocal Leukoencephalopathy Among Ibrutinib Treatment In Chronic Lymphocytic Leukemia.
Çetintepe T; Gediz F; Akyar I; Çetintepe L; Koç AM
J Oncol Pharm Pract; 2022 Jul; 28(5):1249-1253. PubMed ID: 35037793
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.
Hsiehchen D; Arasaratnam R; Raj K; Froehlich T; Anderson L
Oncology; 2018; 95(5):319-322. PubMed ID: 30045034
[TBL] [Abstract][Full Text] [Related]
5. Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
Felli V; Di Sibio A; Anselmi M; Gennarelli A; Sucapane P; Splendiani A; Catalucci A; Marini C; Gallucci M
Neuroradiol J; 2014 Dec; 27(6):657-64. PubMed ID: 25489887
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
[TBL] [Abstract][Full Text] [Related]
7. An autopsy case of progressive multifocal leukoencephalopathy after rituximab therapy for malignant lymphoma.
Muto R; Sugita Y; Momosaki S; Ito Y; Wakugawa Y; Ohshima K
Neuropathology; 2019 Feb; 39(1):58-63. PubMed ID: 30511425
[TBL] [Abstract][Full Text] [Related]
8. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
9. Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma.
Viallard JF; Lazaro E; Lafon ME; Pellegrin JL
Leuk Lymphoma; 2005 Nov; 46(11):1659-62. PubMed ID: 16334909
[TBL] [Abstract][Full Text] [Related]
10. Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir.
Osorio S; de la Cámara R; Golbano N; Marti E; Fedele CG; Nieto S; Manzanares R; Fernández-Rañada JM
Bone Marrow Transplant; 2002 Dec; 30(12):963-6. PubMed ID: 12476291
[TBL] [Abstract][Full Text] [Related]
11. [Progressive multifocal leukoencephalopathy after rituximab therapy in a patient with mantle cell lymphoma].
Ota I; Katsura Y; Yoshida C; Yoshizawa K; Ohtani H; Sata T; Komeno T
Rinsho Ketsueki; 2010 Dec; 51(12):1786-8. PubMed ID: 21258190
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Kaur V; Swami A
J Oncol Pharm Pract; 2017 Apr; 23(3):235-239. PubMed ID: 26970573
[TBL] [Abstract][Full Text] [Related]
14. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy in a patient with lymphoma and presumptive hyper IgE syndrome.
Gocmen R; Acar NP; Cagdas D; Kurne A
J Neurovirol; 2017 Aug; 23(4):632-636. PubMed ID: 28643229
[TBL] [Abstract][Full Text] [Related]
16. [Initial ophthalmic manifestation of a fatal underlying disease : Importance of perimetry in unspecific visual deterioration].
Orphal J; Terai N
Ophthalmologe; 2021 Jun; 118(6):590-592. PubMed ID: 32642881
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
January
Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765
[TBL] [Abstract][Full Text] [Related]
18. [Progressive multifocal leukoencephalopathy in a patient with multiple myeloma].
Willert CB; Engsig FN; Eskildsen HW; Andersen AB
Ugeskr Laeger; 2014 Dec; 176(49):. PubMed ID: 25497861
[TBL] [Abstract][Full Text] [Related]
19. Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab.
Warsch S; Hosein PJ; Morris MI; Teomete U; Benveniste R; Chapman JR; Lossos IS
Int J Hematol; 2012 Aug; 96(2):274-8. PubMed ID: 22684926
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
Zhou X; Steinhardt MJ; Düll J; Krummenast F; Danhof S; Meckel K; Nickel K; Grathwohl D; Leicht HB; Rosenwald A; Einsele H; Rasche L; Kortüm M
Eur J Haematol; 2020 Apr; 104(4):352-355. PubMed ID: 31922303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
